晚期恶性瘤老年患者PRaG治疗的有效性和安全性:一个前性的多中心临床研究协议 (PRaG 9.0研究)
Xiangrong Zhao1,2,3, MengMeng Yang1,2,3, Junjun Zhang1,2,3
1Center for Cancer Diagnosis and Treatment, The Second Affiliated Hospital of Soochow University, Suzhou, China.
Technology in cancer research & treatment
|November 27, 2025
概括
这项研究研究了PRaG疗法,结合免疫疗法和放射疗法,用于老年患者 (75岁以上) 患有晚期固体瘤. 初步结果表明,这种治疗在这个人群中既有效又耐受.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 老年医学 老年医学
背景情况:
- 有限证据表明,免疫疗法对患有恶性固体瘤的老年患者 (75岁以上) 的疗效和安全性是有限的.
- PRaG疗法 (PD-1/PD-L1抑制剂,放射治疗,GM-CSF) 针对的是先进的,耐火性瘤.
- 初步数据表明,PRaG疗法在老年人中具有潜在的益处和良好的耐受性.
研究的目的:
- 评估PRaG疗程在患有晚期恶性固体瘤的老年患者中的疗效和安全性.
- 为在这个特定的老年人群中使用免疫疗法提供基于证据的支持.
- 评估75岁及以上的高级固体瘤患者的治疗结果.
主要方法:
- 一个多中心,前性,单臂II期临床试验.
- 招募了29名75岁及以上的高级实体瘤患者 (新诊断或复发性,转移性).
- 患者至少接受两轮PRaG治疗,直到疾病进展或不可容忍的不良事件.
主要成果:
- 初步发现表明,老年患者 (75岁以上) 可以从PRaG治疗中受益.
- 这种治疗在这个患者群体中似乎耐受得很好.
- 进一步的分析将详细说明具体的疗效和安全结果.
结论:
- PRaG疗法对治疗晚期恶性固体瘤的老年患者有前途.
- 这项研究旨在为老年瘤学中免疫疗法使用提供关键证据.
- 结果将为75岁及以上的患者的PRaG治疗提供临床实践信息.
相关概念视频
01:27Pharmacodynamics in Geriatric Patients: Effects of Age
180
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
180
01:15Drug Dosing: Geriatric Patients
212
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
212
01:22Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption
212
As individuals age, their body's physiology evolves, affecting drug pharmacokinetics. The most apparent changes occur in the gastrointestinal tract, where an increase in gastric pH, a delay in gastric emptying, and a reduction in gastrointestinal motility are observed. Remarkably, these changes do not substantially modify the absorption of orally administered drugs, particularly those absorbed via passive diffusion.Transdermal drug delivery emerges as a highly viable method for older adults due...
212
01:18Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism
183
Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
183
02:56Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K